Quantifying spatial heterogeneity in dynamic contrast-enhanced MRI parameter maps

C. J. Rose1, S. Mills1, J. P. O’Connor1,2, G. Buonaccorsi1, C. Roberts1, Y. Watson1, S. Zhao1, B. Whitcher3, G. Jayson2, A. Jackson1, and G. J. Parker1

1Imaging Science & Biomedical Engineering, The University of Manchester, Manchester, Greater Manchester, United Kingdom, 2Dept. of Medical Oncology, Christie Hospital NHS Trust, Manchester, Greater Manchester, United Kingdom, 3Clinical Imaging Centre, GlaxoSmithKline, London, United Kingdom

INTRODUCTION Dynamic contrast-enhanced (DCE) magnetic resonance imaging is often used in trials of cancer therapies1. Current practice is to describe the contrast agent uptake curve using model-based (e.g. extended Tofts2) or model-free parameters (e.g. the initial area under the curve, IAUC) at each tumour voxel. The tumour may then be summarised as a whole by computing an average value of the chosen parameter. A change in such a summary statistic (such as mean or median values) after drug administration may be used as evidence of drug action. A problem with this approach is that these summary statistics do not consider that most solid tumours are spatially heterogeneous, or that drug-induced effects are often spatially localised. Simple summary statistics neglect this potentially important spatial information. This abstract describes novel summary statistics that we have developed to capture this heterogeneity information using parameters’ values and spatial locations, and applies them to two sets of clinical DCE-MRI data.

METHODS We compute four heterogeneity statistics from the extruded 4-D parameter maps: surface area, volume, ratio of surface area to volume and box-counting fractal dimension3. The box-counting dimension attempts to quantify object complexity and is computed by imposing regular grids of a range of scales on the object and investigating the relationship between scale and the number of grid elements (boxes) that are occupied by the object.

RESULTS We applied our heterogeneity statistics to two sets of clinical DCE-MRI data. In the first experiment, four patients with a total of 25 liver metastases (n=10, n=11, n=7, n=5) underwent DCE-MRI imaging at 1.5T on a Philips Intera System. The patients were scanned at two baseline visits in the week before dosing with an anti-angiogenic compound (though the first baseline scan was missing for patient 4), and then again after drug administration. Routine quality assurance identified 18 suitable tumours. DCE-MRI data were converted to signal intensities and the extended Tofts model was fitted to each tumour voxel, yielding maps of \( K_{trans} \), \( v_p \). 4-D Fractal and extrusion-based heterogeneity statistics were then computed for each parameter map. The tumours were assumed to be independent and non-parametric ANOVAs (Kruskal Wallis) were performed to investigate differences between the baselines and post-treatment scans for each parameter.

In the second experiment we investigated the ability of the heterogeneity statistics to identify meaningful heterogeneity in parameter maps computed for gliomas. Gliomas are histologically graded into four WHO grades4 on the basis of heterogeneity: high grade gliomas are characterised by areas of hypo- and hyper-cellularity corresponding to areas of necrosis and increased cell density, while low grades are less heterogeneous. Subjectively, such characteristics appear to be visible in DCE-MRI images. Nine glioma patients were recruited and, before surgery, underwent DCE-MRI imaging on a 3T Philips Achieva System. All tumours were histologically confirmed to be gliomas and were graded according to WHO criteria: there were 4 low grade (grade II) and 5 high grade (grades III and IV) gliomas. The extrusion-based heterogeneity statistics were computed for each tumour as described above. Differences between heterogeneity statistics for the two groups were investigated using Wilcoxon rank sum tests. Both studies were approved by local research ethics committees and all patients gave written informed consent.

RESULTS In the drug trial experiment, there were significant differences in surface area to volume ratio for extruded \( K_{trans} \) and \( v_p \) maps (\( p=0.0013 \) and \( p=0.045 \) respectively); see Fig. 1. Post hoc testing revealed significant differences between first baseline and post-treatment scans (\( p=0.004 \)) and second baseline and post-treatment scans (\( p=0.001 \)), without Bonferroni-like corrections. As anticipated, there were no significant differences in heterogeneity statistics between the baseline scans. The difference in spread between the first and second baselines (Fig. 1) is explained by the missing data for patient 4. In the glioma experiment there were significant differences between the heterogeneity statistics as grouped by grade for: box dimension computed for extruded \( v_p \); surface area computed for extruded \( K_{trans} \) and \( v_p \); and the volume of extruded \( v_p \) parameter maps (all \( p<0.05 \)); see Fig. 2.

CONCLUSIONS This abstract has described approaches to quantifying heterogeneity in DCE-MRI parameter maps. Experiments using real data have shown that they are sensitive to the effects of an anti-angiogenic drug and glioma grade (which is related to heterogeneity). There was no combination of parameter and statistic that was sensitive in both experiments. However, it is interesting that heterogeneity statistics based upon \( v_p \) were able to achieve significant discrimination in both experiments because this parameter is often assumed to have little physiological importance compared to \( K_{trans} \) and \( v_p \).


ACKNOWLEDGEMENTS Financial support was provided by GlaxoSmithKline and Cancer Research UK.